Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.

O'Leary DH, Reuwer AQ, Nissen SE, Després JP, Deanfield JE, Brown MW, Zhou R, Zabbatino SM, Job B, Kastelein JJ, Visseren FL; AUDITOR investigators.

Heart. 2011 Jul;97(14):1143-50. doi: 10.1136/hrt.2011.223446. Epub 2011 May 24.

PMID:
21610270
2.

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators.

JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.

PMID:
18387931
3.

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group.

JAMA. 2006 Feb 15;295(7):761-75. Erratum in: JAMA. 2006 Mar 15;295(11):1252.

PMID:
16478899
4.

Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.

Crouse JR 3rd, Bots ML, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Raichlen JS; METEOR Study Group.

Eur J Cardiovasc Prev Rehabil. 2010 Apr;17(2):223-9. doi: 10.1097/HJR.0b013e3283359c38.

PMID:
20038840
5.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
6.

A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients.

Vukusich A, Kunstmann S, Varela C, Gainza D, Bravo S, Sepulveda D, Cavada G, Michea L, Marusic ET.

Clin J Am Soc Nephrol. 2010 Aug;5(8):1380-7. doi: 10.2215/CJN.09421209. Epub 2010 Jun 3.

7.

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group.

N Engl J Med. 2005 Nov 17;353(20):2121-34.

8.

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

Hollander P.

Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S29-32.

PMID:
17296341
9.

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen AJ.

J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x. Review.

PMID:
18426513
10.

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O; RIO-Europe Study Group.

Eur Heart J. 2008 Jul;29(14):1761-71. doi: 10.1093/eurheartj/ehn076. Epub 2008 Apr 15.

11.

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.

Després JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):416-23. doi: 10.1161/ATVBAHA.108.176362. Epub 2008 Dec 26.

12.

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.

Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML; METEOR Study Group.

JAMA. 2007 Mar 28;297(12):1344-53. Epub 2007 Mar 25.

PMID:
17384434
13.

Rimonabant: new drug. Obesity: loss of a few kilos, many questions.

[No authors listed]

Prescrire Int. 2006 Aug;15(84):123-6.

PMID:
16977739
15.

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group.

Lancet. 2005 Apr 16-22;365(9468):1389-97. Erratum in: Lancet. 2005 Jul 30-Aug 5;366(9483):370.

PMID:
15836887
16.

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

Christopoulou FD, Kiortsis DN.

J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x. Review.

PMID:
21198716
17.

Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.

Bots ML, Palmer MK, Dogan S, Plantinga Y, Raichlen JS, Evans GW, O'Leary DH, Grobbee DE, Crouse JR 3rd; METEOR Study Group.

J Intern Med. 2009 Jun;265(6):698-707. doi: 10.1111/j.1365-2796.2009.02073.x. Epub 2009 Mar 2.

18.

Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.

Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF; ACTOL Study Investigators.

J Clin Psychopharmacol. 2008 Jun;28(3):317-24. doi: 10.1097/JCP.0b013e318172b8bc.

PMID:
18480689
19.
20.

Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.

Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS.

Heart Vessels. 2011 Sep;26(5):502-10. doi: 10.1007/s00380-010-0093-1. Epub 2010 Dec 9.

PMID:
21153029
Items per page

Supplemental Content

Write to the Help Desk